Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript
Q1 2024 Earnings Call April 25, 2024 Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $-1.32, expectations were $-1.49. Gilead Sciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates
Gilead Sciences (GILD) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to earnings of $1.37 per share a year ago. These figures are adjusted for non-recurring items.
It was a busy week in the biotech sector with earnings reports from bigwigs Gilead Sciences, Inc. GILD and GSK plc GSK. Mergers and acquisitions continue to be in the spotlight as pharma and biotech ...
Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Analyst Salveen Richter of Goldman Sachs maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price target of ...
Gilead Sciences Inc.’s stock dipped 0.2% in after-hours trading Thursday, after the drug company’s adjusted first-quarter ...
Gilead Sciences’ stock underperformed market substantially over past decade. It offers a high 4.61% dividend yield. Read my ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Teladoc (TDOC – Research Report), R1 RCM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback